Skip to content
naulon
Get started

No retraction, correction or concern found when last checked on Oct 21, 2026.

Improving the safety of cell therapy products by suicide gene transfer

Benjamin S. Jones, Lawrence S. Lamb, Frederick Goldman and 1 more

Frontiers in Pharmacology · 2014 · Review

doi:10.3389/fphar.2014.00254

Abstract

Adoptive T-cell therapy can involve donor lymphocyte infusion after allogeneic hematopoietic stem cell transplantation, the administration of tumor infiltrating lymphocyte expanded ex-vivo, or more recently the use of T cell receptor or chimeric antigen receptor redirected T cells. However, cellular therapies can pose significant risks, including graft-vs.-host-disease and other on and off-target effects, and therefore strategies need to be implemented to permanently reverse any sign of toxicity. A suicide gene is a genetically encoded molecule that allows selective destruction of adoptively transferred cells. Suicide gene addition to cellular therapeutic products can lead to selective ablation of gene-modified cells, preventing collateral damage to contiguous cells and/or tissues. The "ideal" suicide gene would ensure the safety of gene modified cellular applications by granting irreversible elimination of "all" and "only" the cells responsible for the unwanted toxicity. This review presents the suicide gene safety systems reported to date, with a focus on the state-of-the-art and potential applications regarding two of the most extensively validated suicide genes, including the clinical setting: herpes-simplex-thymidine-kinase and inducible-caspase-9.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 21, 2026. Paragraph numbers are ours, so an answer can point at one.

Introduction

Adoptive T-cell therapy can involve donor lymphocyte infusion (DLI) after allogeneic hematopoietic stem cell transplantation (allo-HSCT) (Copelan,; Bar et al., ), the administration of tumor infiltrating lymphocyte (TILs) expanded ex-vivo (Dudley et al., ), or more recently the use of T cell receptor (TCR) or chimeric antigen receptor (CAR) redirected T cells (Cieri et al., ).

Cellular therapies are not without risks. Donor T cells within the HSC product or infused post-transplant as DLI have been associated with potentially fatal graft-vs.-host-disease (GVHD) (Copelan, ), whereas administration of engineered T cells has also resulted in on/off target toxicities as well as a cytokine release syndrome (Tey, ).

Unlike small molecules or biologics, cell therapies have a very long, or even an indefinite half-life, therefore since toxicity can be progressive a safety switch is needed in order to eliminate the infused cells in case of adverse events. A suicide gene is a genetically encoded molecule that allows selective destruction of adoptively transferred cells. Suicide gene addition to cellular therapeutic products can lead to selective ablation of gene-modified cells, preventing collateral damage to contiguous cells and/or tissues. The “ideal” suicide gene would ensure the safety of gene modified cellular applications by granting irreversible elimination of “all” and “only” the cells responsible for the unwanted toxicity.

This review presents the suicide gene safety systems reported to date, with a focus on the state-of-the-art and potential applications regarding two of the more extensively validated suicide genes in the clinical setting: herpes-simplex-thymidine-kinase (HSV-TK) and inducible-caspase-9 (iCasp9).

Available suicide gene technologies

Suicide gene technologies can be broadly classified based upon their mechanism of action in metabolic (gene-directed enzyme prodrug therapy, GDEPT), dimerization inducing, and therapeutic monoclonal antibody mediated. The ideal agent for suicide gene activation should be biologically inert, have an adequate bio-availability and bio-distribution profiles, and be characterized by intrinsic acceptable or absent toxicity.

GDEPT (Springer and Niculescu-Duvaz, ) converts a nontoxic drug to a toxic compound in gene-modified cells. Examples include herpes simplex virus thymidine kinase (HSV-TK) (Ciceri et al.,, ), and cytosine deaminase (CD) (Tiraby et al., ). Unlike the mammalian thymidine kinase, HSV-TK is characterized by 1000 fold higher affinity to specific nucleoside analogs (Elion et al., ), including ganciclovir (GCV), making it suitable for use as a suicide gene in mammalian cells. Mechanistically, HSV-TK phosphorylates nucleoside analogs, including acyclovir and GCV, and their resulting triphosphate form incorporates into DNA via the action of DNA polymerase, leading to chain termination and cell death (Moolten, ). HSV-TK/GCV also induces apoptosis through CD95-L independent CD95 aggregation, leading to the formation of a Fas-associated death domain protein (FADD) and caspase-8-containing death-inducing signaling complex (Beltinger et al., ). Similarly, the CD gene encodes cytosine deaminase, which converts 5-fluorocytosine (5-FC) into the cytotoxic 5-fluorouracil (5-FU) (Tiraby et al., ).

Apoptotic genes (e.g., Caspases) eliminate cells by inducing apoptosis (Yamabe et al.,; Carlotti et al.,; Di Stasi et al.,; Zhou et al., ). Chimeric proteins composed of a drug binding domain linked in frame with components of the apoptotic pathway allow conditional dimerization and apoptosis of the transduced cells after administration of a non-therapeutic small molecule dimerizer (Belshaw et al.,; Spencer et al.,; MacCorkle et al.,; Straathof et al., ). Examples include the inducible FAS (iFAS) or inducible Caspase9 (iCasp9)/AP1903 systems (Clackson et al.,; Di Stasi et al., ).

Genetic modification of cells with a protein expressed in the plasma membrane (Hewitt et al., ), allows cell removal after administration of a specific monoclonal antibody. For example, retroviral delivery of the CD20 molecule into T cells and anti-CD20 monoclonal antibody treatment post T cell infusion has been validated in preclinical models as a suicide gene strategy (Introna et al.,; Serafini et al.,; Griffioen et al., ). As an extension of this concept, other interesting pre-clinical models have been investigated: Kieback et al. introduced a 10 amino acid tag of c-myc protein into the TCR sequence allowing elimination after monoclonal antibody administration (Kieback et al., ), whereas a group from London generated a novel compact suicide gene (RQR8) combining epitopes from CD34 and CD20 enabling CD34 selection, cell tracking, as well as deletion after anti-CD20 monoclonal antibody administration (Philip et al., ), and finally, another approach has used truncated human EGFR polypeptide/anti-EGFR monoclonal antibody (Wang et al., ).

The mechanisms of action for the different suicide gene families is depicted in Figure 1, and characteristics of the major suicide gene systems investigated to date for adoptive immunotherapy are listed in Tables 1, 2.

The effectiveness of four suicide gene strategies has been compared in vitro using Epstein Barr virus cytotoxic T cells genetically modified to express HSV-TK, iCasp9, mutant human thymidylate kinase (mTMPK), or human CD20 codon optimized suicide gene. In this study, activation of HSV-TK, iCasp9, and CD20 ultimately resulted in equally effective destruction of transduced T cells. However, while iCasp9 and CD20 effected immediate cell-death induction, HSV-TK-expressing T cells required 3 days of exposure to ganciclovir to reach full effect, and mTMPK-transduced cells showed lower T-cell killing at all time-points (Marin et al., ).

Currently a one size fits all suicide gene is yet to be identified. The best suicide gene strategy should be designed for each specific application, taking into consideration the nature of target cells, the source of the suicide gene, the type of activating agent, the onset of action, and the elimination's kinetic of the target population.

Pre-clinical and clinical data employing the iCasp9 suicide gene system showed preferential elimination of cells with high iCasp9 transgene expression with sparing of quiescent cells. While this can represent an advantage when used for DLI, sparing viral and fungal reactive T cells (Zhou et al., ), complete elimination of CAR/TCR redirected T cells or HSCs may be necessary for the adverse event to abate. Therefore selection of cells with bright transgene expression, or combination of two suicide genes is advisable. Several strategies can be employed to ensure that all the “gene corrected” cells harbor the suicide gene. Cells may be transduced with a bicistronic vector with the suicide gene before an IRES or 2A sequence, or alternatively a selection strategy is used with introduction of a selectable marker.

The source of the suicide gene is also an important component of the strategy design. For example, in contrast to the iCasp9 suicide gene almost completely human derived, viral derived systems, such as HSV-TK, proved immunogenic in immune-competent patients with limited persistence of HSV-TK cells (Traversari et al., ).

Activating agents can also have varying effects, affecting the choice of which suicide gene system utilize for a given application. For example, AP1903 is a biologically inert small molecule dimerizer, whereas ganciclovir can also be used as a therapeutic agent to treat cytomegalovirus reactivation, precluding its use in patients receiving HSV-TK modified cells. The use of therapeutic monoclonal antibodies, in case of CD20 suicide gene or other surface markers, can lead to on-target effects. Therefore the adoption of molecules/antibodies with low toxicity profiles are preferred. Rapid onset of action of iCasp9 may be preferred to shut down a potentially fatal GVHD event. However a more gradual onset of action might be preferred to preserve a graft versus tumor effect.

Finally, resistance mechanisms can develop with these new technologies, and GCV-resistant truncated HSV-TK forms have been observed (Garin et al., ).

Currently, only HSV-TK/GCV and iCasp9/AP1903 have entered clinical trials to enhance the safety of cellular therapeutics for hematologic malignancies.

Clinically validated suicide genes for control of GVHD

Two suicide genes have been validated in the clinic for control of GVHD from administration of donor T cells after HSCT in an effort to enhance immune recovery and maximize graft-vs.-leukemia (GVL) effect: the iCasp9 and the HSV-TK suicide genes. Clinical results are summarized in Table 3.

HSV-TK suicide gene

Bonini et al. demonstrated the efficacy of HSV-TK suicide gene modified T cells in controlling GVHD in 8 patients who received DLI after HSCT for disease relapse or EBV post-transplant lymphoproliferative disease (PTLD). Importantly, a GVL effect attributed to the DLI was demonstrated in five patients (Bonini et al., ).

Subsequently, Tiberghien reported on 12 patients with hematologic malignancies who underwent HLA-matched related donor allo-HSCT (Tiberghien et al., ), and received HSV-TK DLI on the day of transplantation. Treatment with GCV alone resulted in complete remission (CR) in two of the three patients with aGVHD and CR was achieved with the addition of steroids in the third. GCV treatment also resulted in CR for the patient with cGVHD (Tiberghien et al., ).

The anti-tumor effects of HSV-TK DLI was studied in 23 patients with relapsed hematologic malignancies (Oliveira et al., ), where a clinical benefit was demonstrated in 65% of the cases. The development of antibodies against HSV-TK did not preclude a GVL effect, as the patients remained in complete remission thereafter, possibly due either to survival of a low T cell number in the periphery sufficient for immune surveillance, or abrogation of minimal residual disease. Eventually, the gradual elimination of HSV-TK cells can also contribute to a protracted GvL effect. GVHD was successfully controlled abrogated by the safety switch in this trial, as well (Traversari et al., ). Of note, infused T cells persisted in vivo up to 14 years after infusion (Oliveira et al., ). The largest study with 28 patients receiving HSV-TK engineered DLI after T cell depleted haplo-HSCT was published in 2009 (Ciceri et al., ). GVHD was successfully controlled with daily GCV administered for 2 weeks, with no cases of GCV resistance, progression from acute to chronic GVHD, and no GVHD-associated deaths. For patients with primary acute leukemia transplanted in remission the non-relapse mortality at 3 years was 19%. All patients in remission 3 years after transplant remained so in the following years (longest follow up 9 years) (Ciceri et al.,; Oliveira et al., ) Additional indirect evidence suggesting a GVL effect was the finding of de novo loss of mismatched HLA expression on leukemic blasts in one patient at the time of relapse (Vago et al., ).

iCasp9 suicide gene

Spencer et al. and Clackson et al. demonstrated the ability to control signaling pathways through the administration of lipid permeable synthetic ligands, inducing conditional dimerization of intracellular proteins. They generated an inducible Casp9 suicide gene consisting of FKBP12-F36V domain linked, via a flexible Ser-Gly-Gly-Gly-Ser linker, to ΔCaspase 9, which is Caspase without its Caspase activator recruitment domain (Straathof et al., ). FKBP12-F36V consists of a FKBP domain with a substitution at residue 36 of phenylalanine for valine, binding synthetic dimeric ligands, such as AP1903 (Iuliucci et al., ), with high selectivity and subnanomolar affinity. The transgenic cassette was redesigned later to include a truncated CD19 (ΔCD19) molecule, serving as selectable marker to ensure ≥90% purity (Zhou et al.,; Fujimoto et al.,; Tey et al., ). After preclinical validation (Straathof et al.,; Tey et al., ), Brenner and collaborators reported their early results of a phase I clinical trial using the iCasp9 system (Di Stasi et al., ). Recipients of CD34-selected haplo-HSCT for hematological malignancies received escalating doses of iCasp9-modified allo-depleted (Amrolia et al.,; Tey et al., ) T cells from day 30 onwards. The iCasp9-modified T cells expanded and persisted for at least two years in surviving patients. In four patients who developed aGVHD the administration of 0.4 mg/kg AP1903 resulted in apoptosis of ≥90% of iCasp9-modified T cells within 30 min, followed by the rapid (within 24 h) and permanent abrogation of GVHD. Remarkably, residual iCasp9-modified T cells were able to re-expand, contained pathogen-specific precursors, without further GVHD. Although T cells recognizing tumor-associated antigens (TAAs) could be reactivated ex vivo from the peripheral blood before and after AP1903 infusion, three of the four patients receiving AP1903 had disease relapse, compared to only one of six patients who were not so treated, raising the concern that elimination of alloreactive cells would hamper GVL (Zhou et al., ), because of the potential co-expression of minor histocompatibility antigens on hematopoietic and non-hematopoietic tissues (de Bueger et al.,; Wang et al.,; Meadows et al.,; Vogt et al., ). The relative contribution of allo-reactive cells, as compared with TAAs specific T cells is not difficult to quantify, however since most TAAs are aberrantly expressed self-proteins resulting in T cells with low-affinity TCR, it is possible that the alloreactive component is more determinant for GvL. Additionally, although low frequency TAA specific T cells are transferred to patients after allo-HSCT or DLI, they do not persist (Rezvani et al.,, ), potentially due to activation-induced apoptosis (Molldrem et al., ), or terminally differentiated effector memory phenotype (Brenchley et al., ).

Given the successful abrogation of GVHD in vivo, several ongoing clinical trials have replaced the time consuming in vitro allo-depletion step with in vivo allo-depletion using AP1903 for those developing GVHD in the haploidentical (Clinicaltrials.gov identifier NCT01494103; NCT02065869; NCT01744223), or matched related settings, (Clinicaltrials.gov identifier NCT01875237).

In both the HSV-TK and iCasp9 studies, infusion of suicide gene modified cells aided non-gene modified T cell immune reconstitution (Ciceri et al.,; Bondanza et al.,; Di Stasi et al., ), as a consequence of interleukin-7 secretion by gene modified cells (Vago et al., ). The lack of further aGVHD in these studies might suggest either (i) complete elimination of allo-reactive cells, or (ii) development of peripheral tolerance. Additionally, the incidence of cGvHD was low in the HSV-TK T cell studies, and absent in the iCasp9 trial (Di Stasi et al.,; Zhou et al., ), and lymphocytes recovering from infused HSCs did not cause GVHD likely because of thymic education (Vago et al., ).

Suicide genes application for the safety of genetically redirected T cells

TCR (Robbins et al., ) or CAR redirected T cells (Porter et al.,; Kochenderfer et al.,; Brentjens et al., ) have been successful implemented in several clinical trials. However adverse events including autoimmunity or off-target effects have been reported. Autoimmune phenomena manifested because the targeted antigens was shared also on normal tissues, (Yee et al.,; Dudley et al.,; Johnson et al.,; Parkhurst et al.,; Morgan et al., ) whereas off-target cardiac toxicity after high-avidity MAGE-A3 TCR T cells infusion was attributed to cross-reactivity with the Titin peptide in the striated muscles (Linette et al., ). Other toxicities observed included cytokine release syndrome (Brentjens et al.,; Kochenderfer et al., ), organ damage, including a case of fatal acute lung injury (Lamers et al.,,; Morgan et al., ), and hypogammaglobulinemia from depletion of normal B cells (Kochenderfer et al., ). Although strategies including gamma globulin replacement, high dose corticosteroids, or the interleukin 6 receptor blocking antibody, tocilizumab exist for the management of hypogammaglobulinemia or cytokine release (Grupp et al.,; Davila et al., ), the use of a suicide gene is potentially able to irreversibly abrogate such toxicities. Pre-clinical experiments expressing the iCasp9 in conjunction with CAR CD19/CD20 T cells have proven the feasibility of such approach (Hoyos et al.,; Budde et al., ), and a phase 1 clinical trials in patients with sarcoma or neuroblastoma receiving iCasp9 T cells co-expressing a CAR against disialoganglioside GD2 molecule is ongoing (Clinicaltrials.gov identifier NCT01822652 and NCT01953900, respectively). If toxicity is related to the transduced T cells only, selectable markers could be obviated, especially in an autologous setting, provided that all the transduced cells also harbored the suicide gene in order to be eliminated in case of serious adverse events.

Conclusions

Innovative technologies offer compelling opportunities for the optimization of gene therapy based approaches. Successful clinical validation of suicide gene strategies to control GVHD after allo-HSCT is now in advanced phase clinical studies, and introduction of suicide genes in conjunction with CAR modification of T cells for cancer immunotherapy is now undergoing phase 1 clinical testing.

Suicide genes have also been employed as cytotoxic strategy, in vitro and in vivo models (Huber et al.,; Clark et al.,; Nor et al.,; Nakayama et al.,; Hodish et al.,; Evans and Dey,; Duarte et al.,; Mazor et al., ), including combination with replication competent oncolytic viruses (Ahn et al.,; Kaur et al., ), with some evidence of clinical benefit in solid tumors (Pandha et al.,; Freytag et al.,,; Nemunaitis et al.,; Voges et al.,; Li et al.,; Xu et al., ).

Finally, non-integrating vectors (Banasik and McCray, ), strategies for the replacement or correction of defective genes (Narsinh et al.,; Mukherjee and Thrasher,; Li et al., ), together with effective suicide gene strategies, may lead to a more broad application of stem cell or inducible pluripotent stem cell based applications in cancer and regenerative medicine.

Author contributions

All the authors contributed to conception, acquisition, and analysis of data, participated in the manuscript draft preparation, revision and approved and revised the final version.

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References 90

  1. 1.

    Ahn M. Lee S. J. Li X. Jimenez J. A. Zhang Y. P. Bae K. H.. (2009 ). Enhanced combined tumor-specific oncolysis and suicide gene therapy for prostate cancer using M6 promoter. Cancer Gene Ther. 16, 73–82.

    Not in our library10.1038/cgt.2008.59

  2. 2.

    Amrolia P. J. Muccioli-Casadei G. Huls H. Adams S. Durett A. Gee A.. (2006 ). Adoptive immunotherapy with allodepleted donor T-cells improves immune reconstitution after haploidentical stem cell transplantation. Blood 108, 1797–1808.

    Not in our library10.1182/blood-2006-02-001909

  3. 3.

    Banasik M. B. McCray P. B. Jr. (2010 ). Integrase-defective lentiviral vectors: progress and applications. Gene Ther. 17, 150–157.

    Not in our library10.1038/gt.2009.135

  4. 4.

    Bar M. Sandmaier B. M. Inamoto Y. Bruno B. Hari P. Chauncey T.. (2013 ). Donor lymphocyte infusion for relapsed hematological malignancies after allogeneic hematopoietic cell transplantation: prognostic relevance of the initial CD3+ T cell dose. Biol. Blood Marrow Transplant. 19, 949–957.

    Not in our library10.1016/j.bbmt.2013.03.001

  5. 5.

    Belshaw P. J. Spencer D. M. Crabtree G. R. Schreiber S. L. (1996 ). Controlling programmed cell death with a cyclophilin-cyclosporin-based chemical inducer of dimerization. Chem. Biol. 3, 731–738.

    Not in our library10.1016/s1074-5521(96)90249-5

  6. 6.

    Beltinger C. Fulda S. Kammertoens T. Meyer E. Uckert W. Debatin K. M. (1999 ). Herpes simplex virus thymidine kinase/ganciclovir-induced apoptosis involves ligand-independent death receptor aggregation and activation of caspases. Proc. Natl. Acad. Sci. U.S.A. 96, 8699–8704.

    Not in our library10.1073/pnas.96.15.8699

  7. 7.

    Bondanza A. Hambach L. Aghai Z. Nijmeijer B. Kaneko S. Mastaglio S.. (2011 ). IL-7 receptor expression identifies suicide gene–modified allospecific CD8+ T cells capable of self-renewal and differentiation into antileukemia effectors. Blood 117, 6469–6478.

    Not in our library10.1182/blood-2010-11-320366

  8. 8.

    Bonini C. Ferrari G. Verzeletti S. Servida P. Zappone E. Ruggieri L.. (1997 ). HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science 276, 1719–1724.

    Not in our library10.1126/science.276.5319.1719

  9. 9.

    Brenchley J. M. Karandikar N. J. Betts M. R. Ambrozak D. R. Hill B. J. Crotty L. E.. (2003 ). Expression of CD57 defines replicative senescence and antigen-induced apoptotic death of CD8+ T cells. Blood 101, 2711–2720.

    Not in our library10.1182/blood-2002-07-2103

  10. 10.

    Brentjens R. J. Davila M. L. Riviere I. Park J. Wang X. Cowell L. G.. (2013 ). CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci. Transl. Med. 5, 177ra38.

    Not in our library10.1126/scitranslmed.3005930

  11. 11.

    Brentjens R. Yeh R. Bernal Y. Riviere I. Sadelain M. (2010 ). Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial. Mol. Ther. 18, 666–668.

    Not in our library10.1038/mt.2010.31

  12. 12.
    Combining a CD20 Chimeric Antigen Receptor and an Inducible Caspase 9 Suicide Switch to Improve the Efficacy and Safety of T Cell Adoptive Immunotherapy for Lymphoma · 2013
    No notice
  13. 13.

    Carlotti F. Zaldumbide A. Martin P. Boulukos K. E. Hoeben R. C. Pognonec P. (2005 ). Development of an inducible suicide gene system based on human caspase 8. Cancer Gene Ther. 12, 627–639.

    Not in our library10.1038/sj.cgt.7700825

  14. 14.

    Ciceri F. Bonini C. Marktel S. Zappone E. Servida P. Bernardi M.. (2007 ). Antitumor effects of HSV-TK-engineered donor lymphocytes after allogeneic stem-cell transplantation. Blood 109, 4698–4707.

    Not in our library10.1182/blood-2006-05-023416

  15. 15.

    Ciceri F. Bonini C. Stanghellini M. T. Bondanza A. Traversari C. Salomoni M.. (2009 ). Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I-II study. Lancet Oncol. 10, 489–500.

    Not in our library10.1016/s1470-2045(09)70074-9

  16. 16.

    Cieri N. Mastaglio S. Oliveira G. Casucci M. Bondanza A. Bonini C. (2014 ). Adoptive immunotherapy with genetically modified lymphocytes in allogeneic stem cell transplantation. Immunol. Rev. 257, 165–180.

    Not in our library10.1111/imr.12130

  17. 17.

    Clackson T. Yang W. Rozamus L. W. Hatada M. Amara J. F. Rollins C. T.. (1998 ). Redesigning an FKBP-ligand interface to generate chemical dimerizers with novel specificity. Proc. Natl. Acad. Sci. U.S.A. 95, 10437–10442.

    Not in our library10.1073/pnas.95.18.10437

  18. 18.

    Clark A. J. Iwobi M. Cui W. Crompton M. Harold G. Hobbs S.. (1997 ). Selective cell ablation in transgenic mice expression E. coli nitroreductase. Gene Ther. 4, 101–110.

    Not in our library10.1038/sj.gt.3300367

  19. 19.

    Copelan E. A. (2006 ). Hematopoietic stem-cell transplantation. N. Engl. J. Med. 354, 1813–1826.

    Not in our library10.1056/nejmra052638

  20. 20.

    Davila M. L. Riviere I. Wang X. Bartido S. Park J. Curran K.. (2014 ). Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci. Transl. Med. 6, 224ra25.

    Not in our library10.1126/scitranslmed.3008226

  21. 21.

    de Bueger M. Bakker A. Van Rood J. J. Van der Woude F. Goulmy E. (1992 ). Tissue distribution of human minor histocompatibility antigens. Ubiquitous versus restricted tissue distribution indicates heterogeneity among human cytotoxic T lymphocyte-defined non-MHC antigens. J. Immunol. 149, 1788–1794.

    Not in our library

  22. 22.

    Di Stasi A. Tey S. K. Dotti G. Fujita Y. Kennedy-Nasser A. Martinez C.. (2011 ). Inducible apoptosis as a safety switch for adoptive cell therapy. N. Engl. J. Med. 365, 1673–1683.

    Not in our library10.1056/nejmoa1106152

  23. 23.

    Duarte S. Carle G. Faneca H. de Lima M. C. Pierrefite-Carle V. (2012 ). Suicide gene therapy in cancer: where do we stand now? Cancer Lett. 324, 160–170.

    Not in our library10.1016/j.canlet.2012.05.023

  24. 24.

    Dudley M. E. Gross C. A. Somerville R. P. Hong Y. Schaub N. P. Rosati S. F.. (2013 ). Randomized selection design trial evaluating CD8+-enriched versus unselected tumor-infiltrating lymphocytes for adoptive cell therapy for patients with melanoma. J. Clin. Oncol. 31, 2152–2159.

    Not in our library10.1200/jco.2012.46.6441

  25. 25.

    Dudley M. E. Wunderlich J. R. Robbins P. F. Yang J. C. Hwu P. Schwartzentruber D. J.. (2002 ). Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298, 850–854.

    Not in our library10.1126/science.1076514

  26. 26.

    Elion G. B. Furman P. A. Fyfe J. A. de Miranda P. Beauchamp L. Schaeffer H. J. (1977 ). Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl) guanine. Proc. Natl. Acad. Sci. U.S.A. 74, 5716–5720.

    Not in our library10.1073/pnas.74.12.5716

  27. 27.

    Evans G. R. D. Dey D. (2011 ). Suicide Gene Therapy by Herpes Simplex Virus-1 Thymidine Kinase (HSV-TK). Orange, CA: InTech.

    Not in our library

  28. 28.

    Freytag S. O. Movsas B. Aref I. Stricker H. Peabody J. Pegg J.. (2007 ). Phase I trial of replication-competent adenovirus-mediated suicide gene therapy combined with IMRT for prostate cancer. Mol. Ther. 15, 1016–1023.

    Not in our library10.1038/mt.sj.6300120

  29. 29.

    Freytag S. O. Stricker H. Pegg J. Paielli D. Pradhan D. G. Peabody J.. (2003 ). Phase I study of replication-competent adenovirus-mediated double-suicide gene therapy in combination with conventional-dose three-dimensional conformal radiation therapy for the treatment of newly diagnosed, intermediate- to high-risk prostate cancer. Cancer Res. 63, 7497–7506.

    Not in our library

  30. 30.

    Fujimoto M. Poe J. C. Inaoki M. Tedder T. F. (1998 ). CD19 regulates B lymphocyte responses to transmembrane signals. Semin. Immunol. 10, 267–277.

    Not in our library10.1006/smim.1998.9999

  31. 31.

    Garin M. I. Garrett E. Tiberghien P. Apperley J. F. Chalmers D. Melo J. V.. (2001 ). Molecular mechanism for ganciclovir resistance in human T lymphocytes transduced with retroviral vectors carrying the herpes simplex virus thymidine kinase gene. Blood 97, 122–129.

    Not in our library10.1182/blood.v97.1.122

  32. 32.

    Griffioen M. van Egmond E. H. Kester M. G. Willemze R. Falkenburg J. H. Heemskerk M. H. (2009 ). Retroviral transfer of human CD20 as a suicide gene for adoptive T-cell therapy. Haematologica 94, 1316–1320.

    Not in our library10.3324/haematol.2008.001677

  33. 33.

    Grupp S. A. Kalos M. Barrett D. Aplenc R. Porter D. L. Rheingold S. R.. (2013 ). Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N. Engl. J. Med. 368, 1509–1518.

    Not in our library10.1056/nejmoa1215134

  34. 34.

    Hewitt Z. Priddle H. Thomson A. J. Wojtacha D. McWhir J. (2007 ). Ablation of undifferentiated human embryonic stem cells: exploiting innate immunity against the Gal alpha1-3Galbeta1-4GlcNAc-R (alpha-Gal) epitope. Stem Cells 25, 10–18.

    Not in our library10.1634/stemcells.2005-0481

  35. 35.

    Hodish I. Tal R. Shaish A. Varda-Bloom N. Greenberger S. Rauchwerger A.. (2009 ). Systemic administration of radiation-potentiated anti-angiogenic gene therapy against primary and metastatic cancer based on transcriptionally controlled HSV-TK. Cancer Biol. Ther. 8, 424–432.

    Not in our library10.4161/cbt.8.5.7589

  36. 36.

    Hoyos V. Savoldo B. Quintarelli C. Mahendravada A. Zhang M. Vera J.. (2010 ). Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety. Leukemia 24, 1160–1170.

    Not in our library10.1038/leu.2010.75

  37. 37.

    Huber B. E. Richards C. A. Krenitsky T. A. (1991 ). Retroviral-mediated gene therapy for the treatment of hepatocellular carcinoma: an innovative approach for cancer therapy. Proc. Natl. Acad. Sci. U.S.A. 88, 8039–8043.

    Not in our library10.1073/pnas.88.18.8039

  38. 38.

    Introna M. Barbui A. M. Bambacioni F. Casati C. Gaipa G. Borleri G.. (2000 ). Genetic modification of human T cells with CD20: a strategy to purify and lyse transduced cells with anti-CD20 antibodies. Hum. Gene Ther. 11, 611–620.

    Not in our library10.1089/10430340050015798

  39. 39.

    Iuliucci J. D. Oliver S. D. Morley S. Ward C. Ward J. Dalgarno D.. (2001 ). Intravenous safety and pharmacokinetics of a novel dimerizer drug, AP1903, in healthy volunteers. J. Clin. Pharmacol. 41, 870–879.

    Not in our library10.1177/00912700122010771

  40. 40.

    Johnson L. A. Morgan R. A. Dudley M. E. Cassard L. Yang J. C. Hughes M. S.. (2009 ). Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 114, 535–546.

    Not in our library10.1182/blood-2009-03-211714

  41. 41.

    Kaur B. Cripe T. P. Chiocca E. A. (2009 ). “Buy one get one free”: armed viruses for the treatment of cancer cells and their microenvironment. Curr. Gene Ther. 9, 341–355.

    Not in our library10.2174/156652309789753329

  42. 42.

    Kieback E. Charo J. Sommermeyer D. Blankenstein T. Uckert W. (2008 ). A safeguard eliminates T cell receptor gene-modified autoreactive T cells after adoptive transfer. Proc. Natl. Acad. Sci. U.S.A. 105, 623–628.

    Not in our library10.1073/pnas.0710198105

  43. 43.

    Kochenderfer J. N. Dudley M. E. Feldman S. A. Wilson W. H. Spaner D. E. Maric I.. (2012 ). B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 119, 2709–2720.

    Not in our library10.1182/blood-2011-10-384388

  44. 44.

    Lamers C. H. Sleijfer S. van Steenbergen S. van Elzakker P. van Krimpen B. Groot C.. (2013 ). Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity. Mol. Ther. 21, 904–912.

    Not in our library10.1038/mt.2013.17

  45. 45.

    Lamers C. H. Sleijfer S. Vulto A. G. Kruit W. H. Kliffen M. Debets R.. (2006 ). Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. J. Clin. Oncol. 24, e20–e22.

    Not in our library10.1200/jco.2006.05.9964

  46. 46.

    Li M. Suzuki K. Kim N. Y. Liu G. H. Izpisua Belmonte J. C. (2014 ). A cut above the rest: targeted genome editing technologies in human pluripotent stem cells. J. Biol. Chem. 289, 4594–4599.

    Not in our library10.1074/jbc.r113.488247

  47. 47.

    Li N. Zhou J. Weng D. Zhang C. Li L. Wang B.. (2007 ). Adjuvant adenovirus-mediated delivery of herpes simplex virus thymidine kinase administration improves outcome of liver transplantation in patients with advanced hepatocellular carcinoma. Clin. Cancer Res. 13, 5847–5854.

    Not in our library10.1158/1078-0432.ccr-07-0499

  48. 48.

    Linette G. P. Stadtmauer E. A. Maus M. V. Rapoport A. P. Levine B. L. Emery L.. (2013 ). Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. Blood 122, 863–871.

    Not in our library10.1182/blood-2013-03-490565

  49. 49.

    MacCorkle R. A. Freeman K. W. Spencer D. M. (1998 ). Synthetic activation of caspases: artificial death switches. Proc. Natl. Acad. Sci. U.S.A. 95, 3655–3660.

    Not in our library10.1073/pnas.95.7.3655

  50. 50.

    Marin V. Cribioli E. Philip B. Tettamanti S. Pizzitola I. Biondi A.. (2012 ). Comparison of different suicide-gene strategies for the safety improvement of genetically manipulated T cells. Hum. Gene Ther. Methods 23, 376–386.

    Not in our library10.1089/hgtb.2012.050

  51. 51.

    Mazor R. Vassall A. N. Eberle J. A. Beers R. Weldon J. E. Venzon D. J.. (2012 ). Identification and elimination of an immunodominant T-cell epitope in recombinant immunotoxins based on Pseudomonas exotoxin A. Proc. Natl. Acad. Sci. U.S.A. 109, E3597–E3603.

    Not in our library10.1073/pnas.1218138109

  52. 52.

    Meadows L. Wang W. den Haan J. M. Blokland E. Reinhardus C. Drijfhout J. W.. (1997 ). The HLA-A*0201-restricted H-Y antigen contains a posttranslationally modified cysteine that significantly affects T cell recognition. Immunity 6, 273–281.

    Not in our library10.1016/s1074-7613(00)80330-1

  53. 53.

    Molldrem J. J. Lee P. P. Kant S. Wieder E. Jiang W. Lu S.. (2003 ). Chronic myelogenous leukemia shapes host immunity by selective deletion of high-avidity leukemia-specific T cells. J. Clin. Invest. 111, 639–647.

    Not in our library10.1172/jci200316398

  54. 54.

    Moolten F. L. (1986 ). Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. Cancer Res. 46, 5276–5281.

    Not in our library

  55. 55.

    Morgan R. A. Chinnasamy N. Abate-Daga D. Gros A. Robbins P. F. Zheng Z.. (2013 ). Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J. Immunother. 36, 133–151.

    Not in our library10.1097/cji.0b013e3182829903

  56. 56.

    Morgan R. A. Yang J. C. Kitano M. Dudley M. E. Laurencot C. M. Rosenberg S. A. (2010 ). Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol. Ther. 18, 843–851.

    Not in our library10.1038/mt.2010.24

  57. 57.

    Mukherjee S. Thrasher A. J. (2013 ). Gene therapy for PIDs: progress, pitfalls and prospects. Gene 525, 174–181.

    Not in our library10.1016/j.gene.2013.03.098

  58. 58.

    Nakayama K. Pergolizzi R. G. Crystal R. G. (2005 ). Gene transfer-mediated pre-mRNA segmental trans-splicing as a strategy to deliver intracellular toxins for cancer therapy. Cancer Res. 65, 254–263.

    Not in our library

  59. 59.

    Narsinh K. Narsinh K. H. Wu J. C. (2011 ). Derivation of human induced pluripotent stem cells for cardiovascular disease modeling. Cir. Res. 108, 1146–1156.

    Not in our library10.1161/circresaha.111.240374

  60. 60.

    Nemunaitis J. Cunningham C. Senzer N. Kuhn J. Cramm J. Litz C.. (2003 ). Pilot trial of genetically modified, attenuated Salmonella expressing the E. coli cytosine deaminase gene in refractory cancer patients. Cancer Gene Ther. 10, 737–744.

    Not in our library10.1038/sj.cgt.7700634

  61. 61.

    Nor J. E. Hu Y. Song W. Spencer D. M. Nunez G. (2002 ). Ablation of microvessels in vivo upon dimerization of iCaspase-9. Gene Ther. 9, 444–451.

    Not in our library10.1038/sj.gt.3301671

  62. 62.

    Oliveira G. Greco R. Lupo-Stanghellini M. T. Vago L. Bonini C. (2012 ). Use of TK-cells in haploidentical hematopoietic stem cell transplantation. Curr. Opin. Hematol. 19, 427–433.

    Not in our library10.1097/moh.0b013e32835822f5

  63. 63.

    Pandha H. S. Martin L. A. Rigg A. Hurst H. C. Stamp G. W. Sikora K.. (1999 ). Genetic prodrug activation therapy for breast cancer: a phase I clinical trial of erbB-2-directed suicide gene expression. J. Clin. Oncol. 17, 2180–2189.

    Not in our library10.1200/jco.1999.17.7.2180

  64. 64.

    Parkhurst M. R. Yang J. C. Langan R. C. Dudley M. E. Nathan D. A. Feldman S. A.. (2011 ). T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol. Ther. 19, 620–626.

    Not in our library10.1038/mt.2010.272

  65. 65.

    Philip B. Kokalaki E. Mekkaoui L. Thomas S. Straathof K. Flutter B.. (2014 ). A highly compact epitope-based marker/suicide gene for easier and safer T-cell therapy. Blood 124, 1277–1287.

    Not in our library10.1182/blood-2014-01-545020

  66. 66.

    Porter D. L. Levine B. L. Kalos M. Bagg A. June C. H. (2011 ). Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N. Engl. J. Med. 365, 725–733.

    Not in our library10.1056/nejmoa1103849

  67. 67.

    Rezvani K. Brenchley J. M. Price D. A. Kilical Y. Gostick E. Sewell A. K.. (2005 ). T-cell responses directed against multiple HLA-A*0201-restricted epitopes derived from Wilms' tumor 1 protein in patients with leukemia and healthy donors: identification, quantification, and characterization. Clin. Cancer Res. 11, 8799–8807.

    Not in our library10.1158/1078-0432.ccr-05-1314

  68. 68.

    Rezvani K. Price D. A. Brenchley J. M. Kilical Y. Gostick E. Sconocchia G.. (2007 ). Transfer of PR1-specific T-cell clones from donor to recipient by stem cell transplantation and association with GvL activity. Cytotherapy 9, 245–251.

    Not in our library10.1080/14653240701218524

  69. 69.

    Robbins P. F. Morgan R. A. Feldman S. A. Yang J. C. Sherry R. M. Dudley M. E.. (2011 ). Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J. Clin. Oncol. 29, 917–924.

    Not in our library10.1200/jco.2010.32.2537

  70. 70.

    Serafini M. Manganini M. Borleri G. Bonamino M. Imberti L. Biondi A.. (2004 ). Characterization of CD20-transduced T lymphocytes as an alternative suicide gene therapy approach for the treatment of graft-versus-host disease. Hum. Gene Ther. 15, 63–76.

    Not in our library10.1089/10430340460732463

  71. 71.

    Spencer D. M. Belshaw P. J. Chen L. Ho S. N. Randazzo F. Crabtree G. R.. (1996 ). Functional analysis of Fas signaling in vivo using synthetic inducers of dimerization. Curr. Biol. 6, 839–847.

    Not in our library10.1016/s0960-9822(02)00607-3

  72. 72.

    Spencer D. M. Wandless T. J. Schreiber S. L. Crabtree G. R. (1993 ). Controlling signal transduction with synthetic ligands. Science 262, 1019–1024.

    Not in our library10.1126/science.7694365

  73. 73.

    Springer C. J. Niculescu-Duvaz I. (2000 ). Prodrug-activating systems in suicide gene therapy. J. Clin. Invest. 105, 1161–1167.

    Not in our library10.1172/jci10001

  74. 74.

    Straathof K. C. Pule M. A. Yotnda P. Dotti G. Vanin E. F. Brenner M. K.. (2005 ). An inducible caspase 9 safety switch for T-cell therapy. Blood 105, 4247–4254.

    Not in our library10.1182/blood-2004-11-4564

  75. 75.

    Tey S.-K. (2014 ). Adoptive T-cell therapy: adverse events and safety switches. Clin. Transl. Immunol. 3:e17

    Not in our library10.1038/cti.2014.11

  76. 76.

    Tey S. K. Dotti G. Rooney C. M. Heslop H. E. Brenner M. K. (2007 ). Inducible caspase 9 suicide gene to improve the safety of allodepleted T cells after haploidentical stem cell transplantation. Biol. Blood Marrow Transplant. 13, 913–924.

    Not in our library10.1016/j.bbmt.2007.04.005

  77. 77.

    Tiberghien P. Ferrand C. Lioure B. Milpied N. Angonin R. Deconinck E.. (2001 ). Administration of herpes simplex-thymidine kinase-expressing donor T cells with a T-cell-depleted allogeneic marrow graft. Blood 97, 63–72.

    Not in our library10.1182/blood.v97.1.63

  78. 78.

    Tiraby M. Cazaux C. Baron M. Drocourt D. Reynes J. P. Tiraby G. (1998 ). Concomitant expression of E. coli cytosine deaminase and uracil phosphoribosyltransferase improves the cytotoxicity of 5-fluorocytosine. FEMS Microbiol. Lett. 167, 41–49.

    Not in our library10.1111/j.1574-6968.1998.tb13205.x

  79. 79.

    Traversari C. Marktel S. Magnani Z. Mangia P. Russo V. Ciceri F.. (2007 ). The potential immunogenicity of the TK suicide gene does not prevent full clinical benefit associated with the use of TK-transduced donor lymphocytes in HSCT for hematologic malignancies. Blood 109, 4708–4715.

    Not in our library10.1182/blood-2006-04-015230

  80. 80.

    Vago L. Oliveira G. Bondanza A. Noviello M. Soldati C. Ghio D.. (2012 ). T-cell suicide gene therapy prompts thymic renewal in adults after hematopoietic stem cell transplantation. Blood 120, 1820–1830.

    Not in our library10.1182/blood-2012-01-405670

  81. 81.

    Vago L. Perna S. K. Zanussi M. Mazzi B. Barlassina C. Stanghellini M. T.. (2009 ). Loss of mismatched HLA in leukemia after stem-cell transplantation. N. Engl. J. Med. 361, 478–488.

    Not in our library10.1056/nejmoa0811036

  82. 82.

    Voges J. Reszka R. Gossmann A. Dittmar C. Richter R. Garlip G.. (2003 ). Imaging-guided convection-enhanced delivery and gene therapy of glioblastoma. Ann. Neurol. 54, 479–487.

    Not in our library10.1002/ana.10688

  83. 83.

    Vogt M. H. de Paus R. A. Voogt P. J. Willemze R. Falkenburg J. H. (2000 ). DFFRY codes for a new human male-specific minor transplantation antigen involved in bone marrow graft rejection. Blood 95, 1100–1105.

    Not in our library

  84. 84.

    Wang W. Meadows L. R. den Haan J. M. Sherman N. E. Chen Y. Blokland E.. (1995 ). Human H-Y: a male-specific histocompatibility antigen derived from the SMCY protein. Science 269, 1588–1590.

    Not in our library10.1126/science.7667640

  85. 85.

    Wang X. Chang W. C. Wong C. W. Colcher D. Sherman M. Ostberg J. R.. (2011 ). A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells. Blood 118, 1255–1263.

    Not in our library10.1182/blood-2011-02-337360

  86. 86.

    Xu F. Li S. Li X. L. Guo Y. Zou B. Y. Xu R.. (2009 ). Phase I and biodistribution study of recombinant adenovirus vector-mediated herpes simplex virus thymidine kinase gene and ganciclovir administration in patients with head and neck cancer and other malignant tumors. Cancer Gene Ther. 16, 723–730.

    Not in our library10.1038/cgt.2009.19

  87. 87.

    Yamabe K. Shimizu S. Ito T. Yoshioka Y. Nomura M. Narita M.. (1999 ). Cancer gene therapy using a pro-apoptotic gene, caspase-3. Gene Ther. 6, 1952–1959.

    Not in our library10.1038/sj.gt.3301041

  88. 88.

    Yee C. Thompson J. A. Roche P. Byrd D. R. Lee P. P. Piepkorn M.. (2000 ). Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of t cell-mediated vitiligo. J. Exp. Med. 192, 1637–1644.

    Not in our library10.1084/jem.192.11.1637

  89. 89.

    Zhou L. J. Ord D. C. Hughes A. L. Tedder T. F. (1991 ). Structure and domain organization of the CD19 antigen of human, mouse, and guinea pig B lymphocytes. Conservation of the extensive cytoplasmic domain. J. Immunol. 147, 1424–1432.

    Not in our library

  90. 90.

    Zhou X. Di Stasi A. Tey S. K. Krance R. A. Martinez C. Leung K. S.. (2014 ). Long-term outcome after haploidentical stem cell transplant and infusion of T cells expressing the inducible caspase 9 safety transgene. Blood 123, 3895–3905.

    Not in our library10.1182/blood-2014-01-551671

Cited by papers we hold 16

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.